Want to join the conversation?
$LLY said that U.S. FDA approved Portrazza, a necitumumab injection for IV use, 800 mg/50 mL in combination with gemcitabine & cisplatin, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). The approval was based on the results of a Phase III trial named SQUIRE.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.